Fortitude Family Office’s Ligand Pharmaceuticals LGND Stock Holding History

Fortitude Family Office’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58K	Buy	5 +1	+25%	+$236	﹤0.01%	1581
2026 Q1	$799	Buy	4 +3	+300%	+$594	﹤0.01%	1568
2025 Q4	$189	Buy	+1	New	+$192	﹤0.01%	1870

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fortitude Family Office's LGND Position: Q2 2026 in Review

Fortitude Family Office increased its Ligand Pharmaceuticals (LGND) stake by 25% in Q2 2026, buying an estimated $236 and bringing the position to 5 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1581.

Fortitude Family Office first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Fortitude Family Office held 5 shares of Ligand Pharmaceuticals worth $1.58K as of Q2 2026.
Fortitude Family Office bought 1 Ligand Pharmaceuticals share in Q2 2026, an estimated $236.
Ligand Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1581 holding.
Fortitude Family Office first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.